M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Compound CAR T – a double whammy with promise for AML
For the first time, “a compound CAR with two independent CAR units induced remissions in AML.”
News
Adding low-dose ipi to pembro seems safer, still effective for advanced melanoma
An ipilimumab dose of 1 mg/kg appears safer than a 3-mg/kg dose, when given in combination with pembrolizumab to patients with advanced melanoma...
News
Tepotinib elicits responses in METex14 NSCLC
Results with tepotinib establish MET exon 14 as “an actionable target” for non–small cell lung cancer, an investigator said.
News
Nonpharmacologic ankylosing spondylitis recommendations not followed
Disease activity was measured in only 17% of office visits.
News
Inflammatory back pain likely underrecognized in primary care
They “did not seem to be screening for it.”
News
Medicare claims review builds case for NAFLD/NASH screening
Early disease is being missed.
News
Medicare claims review builds case for NAFLD/NASH screening
Early disease is being missed.
News
COVID-19 in pregnancy: Supplement oxygen if saturation dips below 94%
Use high-flow nasal cannula, not positive-pressure ventilation.
News
Results from 11 AHA-funded COVID-19 studies expected within months
The AHA’s COVID-19 and Its Cardiovascular Impact Rapid Response Grant initiative awards $1.2 million in grants.
News
Case series suggests biologics, JAK inhibitors safe during pandemic
Investigators saw no increase in hospitalizations versus the general population in New York City.
News
Yale’s COVID-19 inpatient protocol: Hydroxychloroquine plus/minus tocilizumab
Yale cardiologist offers lessons from “the haze of battle” on fighting COVID-19 with little evidence.
News
Evidence on spironolactone safety, COVID-19 reassuring for acne patients
Observations in Spain – increased prevalence of androgenic alopecia among hospitalized patients – support the androgen link.